Measles Rubella Vaccine : Biological E is developing a measles rubella vaccine. In 2013, Biological E received a commercial grant for
this vaccine from Bill and Melinda Gates Foundation.

Inactivated Polio Vaccine : Biological E and Statens Serum Institut (SSI) entered into a technology transfer arrangement for inactivated
polio vaccine in 2013 and technology transfer was started immediately. Currently in-house process improvement is being done at Nantes, France.

Inactivated Rotavirus Vaccine : Biological E licensed the technology from Centre for Disease Control and Prevention (CDC) in 2012 and the
vaccine is being developed at the company’s facility in Nantes.

Meningitis Vaccine : In 2014, Biological E has started research in order to develop a Men ACWY vaccine.

Biological E respects intellectual property owned by others. Products that are protected under valid patents in respective jurisdictions are not offered or supplied for commercial use. Use of products protected by patent are intended solely for the purpose of Research & Development and for generating data for regulatory submissions.